The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy
B7x is a B7-family ligand with suppressive effects on effector T cells. Here the authors show that tumor-expressed B7x promotes the conversion of conventional CD4+ T cells into regulatory T cells within the tumor microenvironment to promote immune evasion and resistance to anti-CTLA-4 therapy.
Main Authors: | Peter John, Marc C. Pulanco, Phillip M. Galbo, Yao Wei, Kim C. Ohaegbulam, Deyou Zheng, Xingxing Zang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-30143-8 |
Similar Items
-
924 Novel immune checkpoint interactions in Medulloblastoma and the TME
by: Robert Bell, et al.
Published: (2023-11-01) -
Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01) -
254 CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors
by: Yasin Senbabaoglu, et al.
Published: (2020-11-01) -
64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.
by: Kei Higashikawa, et al.
Published: (2014-01-01) -
Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
by: Hsin-Yu Liu, et al.
Published: (2021-09-01)